| 臺大學術典藏 |
2020-08-11T08:36:56Z |
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer
|
Chang Y.-T.; Chang M.-C.; Wei S.-C.; Tien Y.-W.; Hsu C.; PO-CHIN LIANG; Tsao P.-N.; Jan I.-S.; Wong J.-M. |
| 臺大學術典藏 |
2020-08-11T08:36:51Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; PO-CHIN LIANG; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-08-11T08:36:48Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; Wu C.-H.; Hsu C.; Chen C.-H.; Shih T.T.-F.; PO-CHIN LIANG; Liu K.-L. |
| 臺大學術典藏 |
2020-08-11T08:36:46Z |
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide
|
PO-CHIN LIANG; Ch’ang H.-J.; Hsu C.; Chen L.-T.; Shih T.T.F.; Liu T.W. |
| 臺大學術典藏 |
2020-08-11T08:36:45Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; PO-CHIN LIANG; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-08-11T08:36:42Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Po-Chin Liang;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Huo T.-I.; Liao L.-Y.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Lu S.-N. |
| 臺大學術典藏 |
2020-08-07T02:32:19Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; CHIH-HORNG WU; Hsu C.; Chen C.-H.; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2020-08-06T07:51:50Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Liang P.-C.; Liu K.-L.; TIFFANY TING-FANG SHIH; Chen C.-H.; Hsu C.; Wu C.-H.; Chen B.-B.; Shih I.-L. |
| 臺大學術典藏 |
2020-08-06T07:51:48Z |
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide
|
TIFFANY TING-FANG SHIH; Liu T.W.; Chen L.-T.; Hsu C.; Liang P.-C.; Ch’ang H.-J. |
| 臺大學術典藏 |
2020-08-06T07:51:46Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; TIFFANY TING-FANG SHIH |
| 臺大學術典藏 |
2020-08-06T07:51:44Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; TIFFANY TING-FANG SHIH; Hsu C.-Y.; Chen B.-B. |
| 臺大學術典藏 |
2020-07-10T08:16:43Z |
Using standardised measures of health-related quality of life: Critical issues for users and developers
|
Kind, P.;Hsu, C.;Wang, J.-D.;Yao, G.;Tang, J.-L.; Kind, P.; Hsu, C.; Wang, J.-D.; Yao, G.; Tang, J.-L.; KAI-PING GRACE YAO |
| 臺大學術典藏 |
2020-07-09T02:57:04Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-H.; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.; Hsu C.-Y. ;Shen Y.-C. ;Chih-Wei Yu ;Hsu C. ;Hu F.-C. ;Hsu C.-H. ;Chen B.-B. ;Wei S.-Y. ;Cheng A.-L. ;Shih T.T.-F.; Hsu C.-Y.; Shen Y.-C.; CHIH-WEI YU; Hsu C.; Hu F.-C. |
| 臺大學術典藏 |
2020-07-09T02:57:03Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
CHIH-WEI YU; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; Cheng A.-L.; Hsieh R.-K.; Huo T.-I.; Yang T.-S.; Hsu C. |
| 臺大學術典藏 |
2020-07-09T02:57:02Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; CHIH-WEI YU; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-07-09T02:57:01Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.;Hsu C.-Y.;Chih-Wei Yu;Liang P.-C.;Hsu C.;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Hsu C.-Y.; CHIH-WEI YU; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-07-03T08:45:47Z |
Induction of DNA damage-inducible gene GADD45�] contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
|
Chen K.-F; Yu S.-L; Da-Liang Ou;Shen Y.-C;Yu S.-L;Chen K.-F;Yeh P.-Y;Fan H.-H;Feng W.-C;Wang C.-T;Lin L.-I;Hsu C;Cheng A.-L.; DA-LIANG OU; Shen Y.-C; Yeh P.-Y; Fan H.-H; Feng W.-C; Wang C.-T; Lin L.-I; Hsu C; Cheng A.-L. |
| 臺大學術典藏 |
2020-07-03T08:45:44Z |
Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Feng Z.-R; Liou J.-Y; Fan H.-H; Lee B.-S; Hsu C; Cheng A.-L.Ann-Lii; Lin L.-I; Shyue S.-K; Da-Liang Ou;Shyue S.-K;Lin L.-I;Feng Z.-R;Liou J.-Y;Fan H.-H;Lee B.-S;Hsu C;Cheng A.-L.Ann-Lii; DA-LIANG OU |
| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y;Chen B.-B;Da-Liang Ou;Lin Z.-Z;Hsu C.-H;Wang M.-J;Cheng A.-L;Hsu C.; Shao Y.-Y; Chen B.-B; DA-LIANG OU; Lin Z.-Z; Hsu C.-H; Wang M.-J; Cheng A.-L; Hsu C. |
| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Simultaneous visualization of the subfemtomolar expression of microRNA and microRNA target gene using HILO microscopy
|
Lin Y.-Z;Da-Liang Ou;Chang H.-Y;Lin W.-Y;Hsu C;Chang P.-L.; Lin Y.-Z; DA-LIANG OU; Chang H.-Y; Lin W.-Y; Hsu C; Chang P.-L. |
| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
Lin Y.-Y;Tan C.-T;Chen C.-W;Da-Liang Ou;Cheng A.-L;Hsu C.; Lin Y.-Y; Tan C.-T; Chen C.-W; DA-LIANG OU; Cheng A.-L; Hsu C. |
| 臺大學術典藏 |
2020-06-17T03:01:53Z |
Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
|
Ou D.-L.;Shen Y.-C.;Sung-Liang Yu;Chen K.-F.;Yeh P.-Y.;Fan H.-H.;Feng W.-C.;Wang C.-T.;Lin L.-I.;Hsu C.;Cheng A.-L.; Ou D.-L.; Shen Y.-C.; SUNG-LIANG YU; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Hsu C.; Cheng A.-L. |
| 國家衛生研究院 |
2020-05-28 |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang, NJ;Chen, MH;Yang, SH;Hsu, C;Yen, CJ;Tsou, HH;Su, YY;Chen, JS;Shan, YS;Chen, LT |
| 臺大學術典藏 |
2020-05-26T09:27:34Z |
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer
|
Hsu C;Yeh K.-H;Hong R.-L;Chih-Hsin Yang;Lin M.-T;Chen Y.-C;Cheng A.-L.; Hsu C; Yeh K.-H; Hong R.-L; CHIH-HSIN YANG; Lin M.-T; Chen Y.-C; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:31Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H;Cheng A.-L;Hsu C;Chih-Hsin Yang;Lu Y.-S;Lin C.-C;Bu C.-F;Yeh K.-H.; Hsu C.-H; Cheng A.-L; Hsu C; CHIH-HSIN YANG; Lu Y.-S; Lin C.-C; Bu C.-F; Yeh K.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:31Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Perng R.-P.; Chih-Hsin Yang;Tsai C.M;Wang L.S;Lee Y.C;Chang C.J;Lui L.T;Yen S.H;Hsu C;Cheng A.L;Liu M.Y;Chiang S.C;Chen Y.M;Luh K.T;Huang M.H;Yang P.-C;Perng R.-P.; CHIH-HSIN YANG; Tsai C.M; Wang L.S; Lee Y.C; Chang C.J; Lui L.T; Yen S.H; Hsu C; Cheng A.L; Liu M.Y; Chiang S.C; Chen Y.M; Luh K.T; Huang M.H; Yang P.-C |
| 臺大學術典藏 |
2020-05-26T09:27:30Z |
Quality of life of lung cancer patients: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13
|
Chie W.-C;Chih-Hsin Yang;Hsu C;Yang P.-C.; Chie W.-C; CHIH-HSIN YANG; Hsu C; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
|
Kuo S.-H;Chih-Hsin Yang;Yu C.-J;Hsu C;Cheng A.-L;Yang P.-C.; Kuo S.-H; CHIH-HSIN YANG; Yu C.-J; Hsu C; Cheng A.-L; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C;Shen Y.-C;Chih-Hsin Yang;Yeh K.-H;Lu Y.-S;Hsu C.-H;Liu H.-T;Li C.-C;Chen J.-S;Wu C.-Y;Cheng A.-L.; Hsu C; Shen Y.-C; CHIH-HSIN YANG; Yeh K.-H; Lu Y.-S; Hsu C.-H; Liu H.-T; Li C.-C; Chen J.-S; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S;Hsu C;Li C.-C;Kuo S.-H;Yeh K.-H;Chih-Hsin Yang;Hsu C.-H;Wu C.-Y;Cheng A.-L.; Lu Y.-S; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; CHIH-HSIN YANG; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:27Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P;Chih-Hsin Yang;Yu C.-J;Shih J.-Y;Hsu C;Yang P.-C.; Su W.-P; CHIH-HSIN YANG; Yu C.-J; Shih J.-Y; Hsu C; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:26Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Chih-Hsin Yang;Shih J.-Y;Chen K.-C;Yu C.-J;Yang T.-Y;Lin C.-P;Su W.-P;Gow C.-H;Hsu C;Chang G.-C;Yang P.-C.; CHIH-HSIN YANG; Shih J.-Y; Chen K.-C; Yu C.-J; Yang T.-Y; Lin C.-P; Su W.-P; Gow C.-H; Hsu C; Chang G.-C; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C;Yeh K.-H;Chih-Hsin Yang;Hsu C;Tsai Y.-C;Hsu W.-L;Cheng A.-L;Hsu C.-H.; Lin C.-C; Yeh K.-H; CHIH-HSIN YANG; Hsu C; Tsai Y.-C; Hsu W.-L; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Lu Y.-S;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Chih-Hsin Yang; Lin C.-C; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Lin C.-C; Hsu C; Hsu C.-H; Hsu W.-L; Cheng A.-L; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:23Z |
Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers
|
Chih-Hsin Yang;Shih J.-Y;Hsu C;Yu C.-J;Lo Y;Chen J.-P; Chen J.-P; Lo Y; Yu C.-J; Hsu C; Shih J.-Y; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:21Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Lin C.-C; Huang T.-C; Yang P.-C; CHIH-HSIN YANG; Yu C.-J; Shih J.-Y; Cheng A.-L; Hu F.-C; Kuo S.-H; Hsu C; Chih-Hsin Yang;Yang P.-C;Huang T.-C;Lin C.-C;Yu C.-J;Shih J.-Y;Cheng A.-L;Hu F.-C;Kuo S.-H;Hsu C |
| 臺大學術典藏 |
2020-05-26T09:27:06Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Chengb A.-L.;Hsu C.-H;Hong R.-L;Chih-Hsin Yang;Chang D.-Y;Shao Y.-Y;Hu F.-C;Hsu C;Lin Z.-Z; Lin Z.-Z; Hsu C; Hu F.-C; Shao Y.-Y; Chang D.-Y; CHIH-HSIN YANG; Hong R.-L; Hsu C.-H; Chengb A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z;Shau W.-Y;Hsu C;Shao Y.-Y;Yeh Y.-C;Kuo R.N.-C;Hsu C.-H;Chih-Hsin Yang;Cheng A.-L;Lai M.-S.; Lin Z.-Z; Shau W.-Y; Hsu C; Shao Y.-Y; Yeh Y.-C; Kuo R.N.-C; Hsu C.-H; CHIH-HSIN YANG; Cheng A.-L; Lai M.-S. |
| 臺大學術典藏 |
2020-05-26T09:26:58Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F; Chen I.-C; Hsu C; Chang S.-Y; Chien S.-F; Chen Y.-C; Hu F.-C; CHIH-HSIN YANG; Cheng A.-L; Yeh K.-H. |
| 臺大學術典藏 |
2020-05-26T09:26:52Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Lai M.-S.;Chih-Hsin Yang;Cheng A.-L;Cheng W.-F;Hsu C;Shao Y.-Y;Yang Y.-Y;Lai C.-L;Shau W.-Y;Kuo R;Lin Z.-Z;Kuo H.-Y; Kuo H.-Y; Lin Z.-Z; Kuo R; Shau W.-Y; Lai C.-L; Yang Y.-Y; Shao Y.-Y; Hsu C; Cheng W.-F; Cheng A.-L; CHIH-HSIN YANG; Lai M.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:36Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Cheng A.-L; Hsu C; Yang C.-H; Lu Y.-S; Chia-Chi Lin; Bu C.-F; Yeh K.-H.; Hsu C.-H |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Chia-Chi Lin; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:32Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Yang C.-H.;Yang P.-C;Cheng A.-L;Chia-Chi Lin;Hsu C.-H;Yu C.-J;Chang Y.-C;Hsu C;Lin Z.-Z; Lin Z.-Z; Hsu C; Chang Y.-C; Yu C.-J; Hsu C.-H; Chia-Chi Lin; Cheng A.-L; Yang P.-C; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:32Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Hsu C.-H.;Cheng A.-L;Hsu W.-L;Tsai Y.-C;Hsu C;Yang C.-H;Yeh K.-H;Chia-Chi Lin; Chia-Chi Lin; Yeh K.-H; Yang C.-H; Hsu C; Tsai Y.-C; Hsu W.-L; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C; Kuo S.-H; Hu F.-C; Cheng A.-L; Shih J.-Y; Yu C.-J; Chia-Chi Lin; Huang T.-C; Yang P.-C; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma
|
Cheng A.-L.;Chang K.-J;Chen M.M;Bu C.-F;Yen-Shen Lu;Chao T.-Y;Huang C.-S;Hsu C; Hsu C; Huang C.-S; Chao T.-Y; YEN-SHEN LU; Bu C.-F; Chen M.M; Chang K.-J; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C; Yang C.-H; YEN-SHEN LU; Lin C.-C; Bu C.-F; Yeh K.-H.; Yeh K.-H.;Bu C.-F;Lin C.-C;Yen-Shen Lu;Yang C.-H;Hsu C;Cheng A.-L;Hsu C.-H; Hsu C.-H; Cheng A.-L |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Phase II study of combination doxorubicin, interferon-�\, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Cheng A.-L.;Wu C.-Y;Hsu C.-H;Yang C.-H;Yeh K.-H;Kuo S.-H;Li C.-C;Hsu C;Yen-Shen Lu; YEN-SHEN LU; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; Yang C.-H; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Cheng A.-L.;Wu C.-Y;Chen J.-S;Li C.-C;Liu H.-T;Hsu C.-H;Yen-Shen Lu;Yeh K.-H;Yang C.-H;Shen Y.-C;Hsu C; Hsu C; Shen Y.-C; Yang C.-H; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Liu H.-T; Li C.-C; Chen J.-S; Wu C.-Y; Cheng A.-L. |
